Visual AcuityNCT05601544

The Effects of Contact Lenses With UV/HEV-Filter on Visual Function

A study testing ACUVUE OASYS 1-Day, ACUVUE OASYS MAX 1-Day and ACUVUE OASYS Multifocal in people with Visual Acuity, run by Johnson & Johnson Vision Care, Inc. at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

This is a 2-phase, single-site, non-dispensing, randomized, controlled, double-masked, 2x2 crossover study to objectively measure potential benefits of a new UV/HEV filter using psychophysical testing techniques. Read more about this study

Who is it for?: Ages 18 to 70 yearsHealthy volunteers can take part
Conditions the study is for: Visual Acuity
What is being tested?: ACUVUE OASYS 1-Day, ACUVUE OASYS MAX 1-Day and ACUVUE OASYS Multifocal
Type of treatment: Medical device
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 145 participants
Where: 1 siteUnited States
Study dates: 9 Dec 2022to 17 Nov 2023
Phase: Interventional
Are there results?: Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 to 70 years
All sexes
Healthy volunteers accepted
Adult, Older adult

Who may be able to join

Potential subjects must satisfy all of the following criteria to be enrolled in the study:
The subject must:
Read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.
Appear able and willing to adhere to the instructions set forth in this clinical protocol.
Be between 18 and 70 (inclusive) years of age at the time of screening.
By self-report, habitually wear soft contact lenses (sphere, multifocal, toric) in both eyes in a daily reusable or daily disposable wear modality (i.e. not extended wear modality). Habitual wear is defined as a minimum of 6 hours of wear per day, for a minimum of 5 days per week during the past 30 days.

Show all 10Show fewer

If applicable, those subjects receiving the spherical lenses will need a vertex-corrected distance refraction within the range of -1.00 through -6.00 DS
If applicable, those subjects receiving the multifocal lenses will need a vertex-corrected distance refraction within the range of -1.00 through -6.00 DS
If applicable, those subjects receiving the toric lenses will need a vertex-corrected distance refraction within the range of -1.50 through -4.00 DS, -0.625 through -1.625 DC, and cylinder axes: 80/90/100, 170/180/10
The best corrected, monocular, distance visual acuity must be 20/25 or better in each eye

Who cannot join

Potential subjects who meet any of the following criteria will be excluded from participating in the study:
The subject must not:
Be currently pregnant or lactating.
Be currently using any ocular medications or have any ocular infection of any type.
By self-report, have any ocular or systemic disease, allergies, infection, or use of medication that the investigator believes might contraindicate or interfere with contact lens wear, or otherwise compromise study endpoints, including infectious disease (e.g., hepatitis, tuberculosis), contagious immunosuppressive disease (e.g., Human Immunodeficiency Virus [HIV]), autoimmune disease (e.g. rheumatoid arthritis, Sjögren's syndrome), or history of serious mental illness or seizures. See section 9.1 for additional details regarding excluded systemic medications.
Have habitually worn rigid gas permeable (RGP) lenses, orthokeratology lenses, or hybrid lenses (e.g. SynergEyes, SoftPerm) within the past 6 months.

Show all 14Show fewer

Be currently wearing lenses in an extended wear modality.
Have participated in a contact lens or lens care product clinical trial within 14 days prior to study enrollment.
Be an employee (e.g., Investigator, Coordinator, Technician) or immediate family member of an employee (including partner, child, parent, grandparent, grandchild or sibling of the employee or their spouse) of the clinical site.
(Phase 2 only): Have participated in Phase 1 of the study.
Have clinically significant (grade 3 or higher on the FDA grading scale) slit lamp findings (e.g., corneal edema, neovascularization or staining, tarsal abnormalities or bulbar injection) or other corneal or ocular disease or abnormalities that the investigator believes might contraindicate contact lens wear or may otherwise compromise study endpoints (including entropion, ectropion, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, aphakia, moderate or above corneal distortion, herpetic keratitis).
Have a history of strabismus or amblyopia.
Have fluctuations in vision due to clinically significant dry eye or other ocular conditions.
Have had or have planned (within the study period) any ocular or intraocular surgery (e.g., radial keratotomy, PRK, LASIK, iridotomy, retinal laser photocoagulation, etc.).

Trial locations and contacts

1 site in 1 country.

United States1 site

The University of Georgia
Athens, Georgia, 30602

Other trials in United States

About this study

Conditions: Visual Acuity
Being tested: ACUVUE OASYS 1-Day, ACUVUE OASYS MAX 1-Day, ACUVUE OASYS Multifocal, ACUVUE OASYS MAX 1-Day Multifocal, ACUVUE OASYS 1-Day for Astigmatism

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

ACUVUE OASYS 1-DayDevice
Sphere CONTROL
ACUVUE OASYS MAX 1-DayDevice
Sphere TEST
ACUVUE OASYS MultifocalDevice
Multifocal CONTROL
ACUVUE OASYS MAX 1-Day MultifocalDevice
Multifocal TEST
ACUVUE OASYS 1-Day for AstigmatismDevice
Toric CONTROL
senofilcon A based contact lens (toric) with new UV/HEV filterDevice
Toric TEST

Study groups in NCT05601544
Study group	Role	What they receive
Sphere TEST/CONTROL	Experimental	Eligible subjects who are habitual wearers of soft contact lenses that receive the sphere lenses will be randomized into the sphere TEST/CONTROL sequence. Receives: Device: ACUVUE OASYS 1-Day; Device: ACUVUE OASYS MAX 1-Day
Sphere CONTROL/TEST	Experimental	Eligible subjects who are habitual wearers of soft contact lenses that receive the sphere lenses will be randomized into the sphere CONTROL/TEST sequence. Receives: Device: ACUVUE OASYS 1-Day; Device: ACUVUE OASYS MAX 1-Day
Multifocal TEST/CONTROL	Experimental	Eligible subjects who are habitual wearers of soft contact lenses that receive the multifocal lenses will be randomized into the multifocal TEST/CONTROL sequence. Receives: Device: ACUVUE OASYS Multifocal; Device: ACUVUE OASYS MAX 1-Day Multifocal
Multifocal CONTROL/TEST	Experimental	Eligible subjects who are habitual wearers of soft contact lenses that receive the multifocal lenses will be randomized into the multifocal CONTROL/TEST sequence. Receives: Device: ACUVUE OASYS Multifocal; Device: ACUVUE OASYS MAX 1-Day Multifocal
Toric TEST/CONTROL	Experimental	Eligible subjects who are habitual wearers of soft contact lenses that receive the toric lenses will be randomized into the toric TEST/CONTROL sequence. Receives: Device: ACUVUE OASYS 1-Day for Astigmatism; Device: senofilcon A based contact lens (toric) with new UV/HEV filter
Toric CONTROL/TEST	Experimental	Eligible subjects who are habitual wearers of soft contact lenses that receive the toric lenses will be randomized into the toric CONTROL/TEST sequence. Receives: Device: ACUVUE OASYS 1-Day for Astigmatism; Device: senofilcon A based contact lens (toric) with new UV/HEV filter

What is being measured

The primary outcome is the main question the study is designed to answer.

Visual Range at Phase 1
Visual range is defined as the log relative energy of simulated haze needed to obscure an otherwise high contrast grating target. Better visual range is indicated by a higher log-relative energy (LRE) of simulated haze (more haze) to obscure an otherwise highly visible target.
Measured: Approximately 15 minutes post lens fitting
Visual Range at Phase 2
Visual range is defined as the log relative energy of simulated haze needed to obscure an otherwise high contrast grating target. Better visual range is indicated by a higher log-relative energy (LRE) of simulated haze (more haze) to obscure an otherwise highly visible target.
Measured: Approximately 15 minutes post lens fitting
Motion Detection at Phase 1
Motion detection is defined as the distance needed (in mm) to determine that a test light has moved from a standard position. Better motion detection is indicated by a smaller distance needed to detect that movement has occurred.
Measured: Approximately 15 minutes post lens fitting
Brightness Perception at Phase 1
Brightness perception is defined as the log- relative energy needed to match a standard stimulus to a natural scene, across 10 different projected scenes. The perception of brighter image is indicated by a higher log-relative energy (LRE) needed to match the initially dim standard to the target.
Measured: Approximately 15 minutes post lens fitting

Secondary outcomes (2)

Motion Detection at Phase 2
Motion detection is defined as the distance needed (in mm) to determine that a test light has moved from a standard position. Better motion detection is indicated by a smaller distance needed to detect that movement has occurred.
Measured: Approximately 15 minutes post lens fitting
Brightness Perception at Phase 2
Brightness perception is defined as the log- relative energy needed to match a standard stimulus to a natural scene, across 10 different projected scenes. The perception of brighter image is indicated by a higher log-relative energy (LRE) needed to match the initially dim standard to the target.
Measured: Approximately 15 minutes post lens fitting

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

9 Dec 202217 Nov 2023

First posted1 Nov 2022
Study start9 Dec 2022
Primary completion17 Nov 2023
Study completion17 Nov 2023

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
Other trials for Visual AcuityStudies of the same condition, open and under way.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase N/A
Primary purpose: Treatment
Allocation: Randomised
Intervention model: Crossover
Masking: Double blind
Who is masked: Participant, Investigator
Enrolment: 145 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT05601544
Sponsor's protocol ID: CR-6480
Status last verified: Apr 2025
First submitted: 27 Oct 2022
Last updated: 27 Apr 2025
Results posted: Yes, on ClinicalTrials.gov
FDA-regulated drug: No
FDA-regulated device: Yes
Individual data sharing: Yes: Johnson \& Johnson Medical Device Companies have an agreement with the Yale Open Data Access (YODA) to serve as the independent review panel for evaluation of requests for clinical study reports and participant level data from investigators and physicians for scientific research that will advance medical knowledge and public health. Requests for access to the study data can be submitted through the YODA Project site at http://yoda.yale.edu

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Recruiting
Implementing AI-based Glaucoma Screening Within Federally Qualified Health Centers
Glaucoma, Ocular Hypertension
Recruiting
Comparison of ACUVUE® OASYS MAX 1-Day Multifocal and DAILIES® AquaComfort Plus® Multifocal
Visual Acuity
Active, not recruiting
Evaluation of Approved Contact Lenses (CR-6657)
Visual Acuity
RecruitingPhase 3
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
Neovascular Age-related Macular Degeneration
Active, not recruitingPhase 2
Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]
Neovascular Age-related Macular Degeneration

All Visual Acuity trials

Study at a glance

From the registry record, last updated by the sponsor on 27 Apr 2025. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: The Effects of Contact Lenses With UV/HEV-Filter on Visual Function
ClinicalTrials.gov ID: NCT05601544
Acronym / sponsor ID: CR-6480
Conditions: Visual Acuity
Study type: Interventional
Recruitment status: Completed
Enrolment: 145 participants (actual)
Lead sponsor: Johnson & Johnson Vision Care, Inc.Industry (pharma, biotech, devices)
Study start: 9 Dec 2022 (actual)
Primary completion: 17 Nov 2023 (actual)
Study completion: 17 Nov 2023 (actual)
First posted: 1 Nov 2022 (actual)
Results: Posted 27 Dec 2024

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Study design

Primary purpose: Treatment
Allocation: Randomised
Intervention model: Crossover
Masking: Double blind (participant, investigator)
Number of arms: 6

Arm	Type	Receives
Sphere TEST/CONTROL	Experimental	Device: ACUVUE OASYS 1-Day, Device: ACUVUE OASYS MAX 1-DayEligible subjects who are habitual wearers of soft contact lenses that receive the sphere lenses will be randomized into the sphere TEST/CONTROL sequence.
Sphere CONTROL/TEST	Experimental	Device: ACUVUE OASYS 1-Day, Device: ACUVUE OASYS MAX 1-DayEligible subjects who are habitual wearers of soft contact lenses that receive the sphere lenses will be randomized into the sphere CONTROL/TEST sequence.
Multifocal TEST/CONTROL	Experimental	Device: ACUVUE OASYS Multifocal, Device: ACUVUE OASYS MAX 1-Day MultifocalEligible subjects who are habitual wearers of soft contact lenses that receive the multifocal lenses will be randomized into the multifocal TEST/CONTROL sequence.
Multifocal CONTROL/TEST	Experimental	Device: ACUVUE OASYS Multifocal, Device: ACUVUE OASYS MAX 1-Day MultifocalEligible subjects who are habitual wearers of soft contact lenses that receive the multifocal lenses will be randomized into the multifocal CONTROL/TEST sequence.
Toric TEST/CONTROL	Experimental	Device: ACUVUE OASYS 1-Day for Astigmatism, Device: senofilcon A based contact lens (toric) with new UV/HEV filterEligible subjects who are habitual wearers of soft contact lenses that receive the toric lenses will be randomized into the toric TEST/CONTROL sequence.
Toric CONTROL/TEST	Experimental	Device: ACUVUE OASYS 1-Day for Astigmatism, Device: senofilcon A based contact lens (toric) with new UV/HEV filterEligible subjects who are habitual wearers of soft contact lenses that receive the toric lenses will be randomized into the toric CONTROL/TEST sequence.

Who may qualify

Ages: 18 to 70 years
Sex: All
Healthy volunteers: Accepted
Age groups: Adult, Older adult

Key inclusion criteria (10 listed)

Potential subjects must satisfy all of the following criteria to be enrolled in the study:
Read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.
Appear able and willing to adhere to the instructions set forth in this clinical protocol.
Be between 18 and 70 (inclusive) years of age at the time of screening.
By self-report, habitually wear soft contact lenses (sphere, multifocal, toric) in both eyes in a daily reusable or daily disposable wear modality (i.e. not extended wear modality). Habitual wear is defined as a minimum of 6 hours of wear per day, for a minimum of 5 days per week during the past 30 days.

Key exclusion criteria (14 listed)

Potential subjects who meet any of the following criteria will be excluded from participating in the study:
Be currently pregnant or lactating.
Be currently using any ocular medications or have any ocular infection of any type.
By self-report, have any ocular or systemic disease, allergies, infection, or use of medication that the investigator believes might contraindicate or interfere with contact lens wear, or otherwise compromise study endpoints, including infectious disease (e.g., hepatitis, tuberculosis), contagious immunosuppressive disease (e.g., Human Immunodeficiency Virus [HIV]), autoimmune disease (e.g. rheumatoid arthritis, Sjögren's syndrome), or history of serious mental illness or seizures. See section 9.1 for additional details regarding excluded systemic medications.
Have habitually worn rigid gas permeable (RGP) lenses, orthokeratology lenses, or hybrid lenses (e.g. SynergEyes, SoftPerm) within the past 6 months.

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
ACUVUE OASYS 1-DaySphere CONTROL	Device	Sphere CONTROL/TEST, Sphere TEST/CONTROL
ACUVUE OASYS MAX 1-DaySphere TEST	Device	Sphere CONTROL/TEST, Sphere TEST/CONTROL
ACUVUE OASYS MultifocalMultifocal CONTROL	Device	Multifocal CONTROL/TEST, Multifocal TEST/CONTROL
ACUVUE OASYS MAX 1-Day MultifocalMultifocal TEST	Device	Multifocal CONTROL/TEST, Multifocal TEST/CONTROL
ACUVUE OASYS 1-Day for AstigmatismToric CONTROL	Device	Toric CONTROL/TEST, Toric TEST/CONTROL
senofilcon A based contact lens (toric) with new UV/HEV filterToric TEST	Device	Toric CONTROL/TEST, Toric TEST/CONTROL

Primary outcome

Visual Range at Phase 1
Time frame: Approximately 15 minutes post lens fitting
Visual range is defined as the log relative energy of simulated haze needed to obscure an otherwise high contrast grating target. Better visual range is indicated by a higher log-relative energy (LRE) of simulated haze (more haze) to obscure an otherwise highly visible target.
Visual Range at Phase 2
Time frame: Approximately 15 minutes post lens fitting
Visual range is defined as the log relative energy of simulated haze needed to obscure an otherwise high contrast grating target. Better visual range is indicated by a higher log-relative energy (LRE) of simulated haze (more haze) to obscure an otherwise highly visible target.
Motion Detection at Phase 1
Time frame: Approximately 15 minutes post lens fitting
Motion detection is defined as the distance needed (in mm) to determine that a test light has moved from a standard position. Better motion detection is indicated by a smaller distance needed to detect that movement has occurred.
Brightness Perception at Phase 1
Time frame: Approximately 15 minutes post lens fitting
Brightness perception is defined as the log- relative energy needed to match a standard stimulus to a natural scene, across 10 different projected scenes. The perception of brighter image is indicated by a higher log-relative energy (LRE) needed to match the initially dim standard to the target.

2 secondary outcomes

Motion Detection at Phase 2
Time frame: Approximately 15 minutes post lens fitting
Brightness Perception at Phase 2
Time frame: Approximately 15 minutes post lens fitting

Results and safety

Results posted to the registry on 27 Dec 2024, as reported by the sponsor. Figures are copied from the record, not re-analysed. Full results on ClinicalTrials.gov.

Participant flow

Group	Started	Completed
Senofilcon A (Test) / Senofilcon A (Control) Sphere Strata	5	5
Senofilcon A (Control)/ Senofilcon A (Test) Sphere Strata	6	6
Senofilcon A (Test) / Senofilcon A (Control) Multifocal Strata	5	5
Senofilcon A (Control) / Senofilcon A (Test) Multifocal Strata	5	5
Senofilcon A (Test) / Senofilcon A (Control) Toric Strata	0	0
Senofilcon A (Control) / Senofilcon A (Control) Toric Strata	0	0

Primary outcome: Visual Range at Phase 1

Time frame: Approximately 15 minutes post lens fitting. Mean (Standard Deviation). Unit: log relative energy level

Measure	Senofilcon A (Test) Sphere Strata - Phase 1 n = 11	Senofilcon A (Control) Sphere Strata - Phase 1 n = 11	Senofilcon A (Test) Multifocal Strata - Phase 1 n = 10	Senofilcon A (Control) Multifocal Strata - Phase 1 n = 10
Value	3.232 (0.1658)	3.049 (0.2101)	3.287 (0.1824)	3.167 (0.1072)

Population analysed: All randomized subjects regardless of actual treatment and subsequent withdrawal from the study or deviation from the protocol.

Primary outcome: Visual Range at Phase 2

Time frame: Approximately 15 minutes post lens fitting. Mean (Standard Deviation). Unit: log relative energy level

Measure	Senofilcon A (Test) Sphere Strata - Phase 2 n = 40	Senofilcon A (Control) Sphere Strata - Phase 2 n = 41	Senofilcon A (Test) Multifocal Strata - Phase 2 n = 40	Senofilcon A (Control) Multifocal Strata - Phase 2 n = 40
Value	3.377 (0.1489)	3.156 (0.1181)	3.181 (0.1649)	3.020 (0.1412)

Senofilcon A (Test) Sphere Strata - Phase 2 vs Senofilcon A (Control) Sphere Strata - Phase 2: Least-squares Mean difference: 0.22 (95% CI 0.19 to 0.25), p <.0001, Mixed Model Analysis
Senofilcon A (Test) Multifocal Strata - Phase 2 vs Senofilcon A (Control) Multifocal Strata - Phase 2: Least-squares Mean difference: 0.16 (95% CI 0.14 to 0.18), p <.0001, Mixed Model Analysis

Population analysed: All randomized subjects regardless of actual treatment and subsequent withdrawal from the study or deviation from the protocol. Based on the pre-specified primary analyses for Phase 2, the primary hypothesis testing was performed for Sphere and Multifocal strata only.

Primary outcome: Motion Detection at Phase 1

Time frame: Approximately 15 minutes post lens fitting. Mean (Standard Deviation). Unit: mm

Measure	Senofilcon A (Test) Sphere Strata - Phase 1 n = 11	Senofilcon A (Control) Sphere Strata - Phase 1 n = 11	Senofilcon A (Test) Multifocal Strata - Phase 1 n = 10	Senofilcon A (Control) Multifocal Strata - Phase 1 n = 10
Value	1.725 (1.3575)	2.881 (1.9824)	3.229 (2.3248)	2.716 (3.1286)

Population analysed: All randomized subjects regardless of actual treatment and subsequent withdrawal from the study or deviation from the protocol. Subject were analyzed per planned randomized treatment.

Primary outcome: Brightness Perception at Phase 1

Time frame: Approximately 15 minutes post lens fitting. Mean (Standard Deviation). Unit: log relative energy

Measure	Senofilcon A (Test) Sphere Strata - Phase 1 n = 11	Senofilcon A (Control) Sphere Strata - Phase 1 n = 11	Senofilcon A (Test) Multifocal Strata - Phase 1 n = 10	Senofilcon A (Control) Multifocal Strata - Phase 1 n = 10
Value	1.109 (0.0909)	1.081 (0.1494)	1.101 (0.1388)	1.041 (0.2222)

2 secondary outcomes are reported in the full results.

Adverse events

Time frame: Time Frame: Throughout the duration of the study (Phase 1 and Phase 2); approximately 1 month per subject.. Other adverse events reported at 5% frequency or more

Group	Serious adverse events	Other adverse events	Deaths
Senofilcon A (Test) Sphere Strata - Phase 1	0 of 11 (0%)	0 of 11 (0%)	0 of 11
Senofilcon A (Control) Sphere Strata - Phase 1	0 of 11 (0%)	0 of 11 (0%)	0 of 11
Senofilcon A (Test) Multifocal Strata - Phase 1	0 of 10 (0%)	0 of 10 (0%)	0 of 10
Senofilcon A (Control) Multifocal Strata - Phase 1	0 of 10 (0%)	0 of 10 (0%)	0 of 10
Senofilcon A (Test) Sphere Strata - Phase 2	0 of 40 (0%)	0 of 40 (0%)	0 of 40
Senofilcon A (Control) Sphere Strata - Phase 2	0 of 41 (0%)	0 of 41 (0%)	0 of 41
Senofilcon A (Test) Multifocal Strata - Phase 2	0 of 40 (0%)	0 of 40 (0%)	0 of 40
Senofilcon A (Control) Multifocal Strata - Phase 2	0 of 40 (0%)	0 of 40 (0%)	0 of 40
Senofilcon A (Test) Toric Strata - Phase 2	0 of 40 (0%)	0 of 40 (0%)	0 of 40
Senofilcon A (Control) Toric Strata - Phase 2	0 of 40 (0%)	0 of 40 (0%)	0 of 40

Loading the posted results from ClinicalTrials.gov…

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 27 Apr 2025.
Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Individual participant dataSharing planned: Yes. Johnson \& Johnson Medical Device Companies have an agreement with the Yale Open Data Access (YODA) to serve as the independent review panel for evaluation of requests for clinical study reports and participant level data from investigators and physicians for scientific research that will advance medical knowledge and public health. Requests for access to the study data can be submitted through the YODA Project site at http://yoda.yale.edu

Related trials for Visual Acuity

Recruiting
Implementing AI-based Glaucoma Screening Within Federally Qualified Health Centers
Glaucoma, Ocular Hypertension
Recruiting
Comparison of ACUVUE® OASYS MAX 1-Day Multifocal and DAILIES® AquaComfort Plus® Multifocal
Visual Acuity
Active, not recruiting
Evaluation of Approved Contact Lenses (CR-6657)
Visual Acuity
RecruitingPhase 3
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
Neovascular Age-related Macular Degeneration
Active, not recruitingPhase 2
Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]
Neovascular Age-related Macular Degeneration

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

Johnson & Johnson Vision Care, Inc. Clinical Trial study director

Johnson & Johnson Vision Care, Inc.

1 site in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A study testing ACUVUE OASYS 1-Day, ACUVUE OASYS MAX 1-Day and ACUVUE OASYS Multifocal in people with Visual Acuity, run by Johnson & Johnson Vision Care, Inc. at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 10 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 27 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 27 Dec 2024). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Visual Range at Phase 1 (time frame: Approximately 15 minutes post lens fitting). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05601544.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Apr 2025.